OncLive TV

Rachna Shroff, MD, MS, FASCO, discusses the efficacy of nab-paclitaxel plus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancer.

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

Lakshmi Nayak, MD, discusses the mechanism of action of emavusertib and the study of this drug relapsed/refractory primary and secondary CNS lymphoma.

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.

Kathryn E. Beckermann, MD, PhD, details the role of tivozanib as second- and third-line therapy in patients with locally advanced or metastatic ccRCC.

Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.

Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Douglas B. Flora, MD, LSSBB, discusses the rationale for assessing BXQ-350 plus mFOLFOX7 and bevacizumab in a phase 1/2 trial of patients with mCRC.

Hideaki Bando, MD, PhD, discusses efficacy outcomes with TAS-102 as a pre-emptive treatment in patients with MRD-positive CRC following curative resection.

Daniel DeAngelo, MD, PhD, discusses the need for consensus guidelines in the management of ALL, particularly in defining optimal treatment strategies for older adult patients.

Neeta Somaiah, MD, discusses chemotherapy as the current mainstay of treatment in sarcoma subtypes and the emergence of immunotherapies in the space.

Mazyar Shadman, MD, MPH, discusses the need for a clinical consensus in selecting optimal treatment strategies in diffuse large B-cell lymphoma.

Rami Komrokji, MD, discusses the importance of establishing a clinical consensus to standardize the use of molecular testing in myelodysplastic syndromes.

Amrita Krishnan, MD, discusses the challenges in developing a clinical consensus on risk stratification in smoldering multiple myeloma and its role in guiding treatment decisions.

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Elizabeth A. Brem, MD, highlights upcoming changes in the follicular lymphoma treatment paradigm that could move the field beyond chemotherapy.

Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Rohan Garje, MD, discusses clinical outcomes among patients with invasive primary urethral cancer based on varying treatment approaches and histology.

Sia Daneshmand MD, discusses key efficacy findings from the SunRISE-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk NMIBC with CIS.

D. Ross Camidge, MD, PhD, discusses the benefits of biomarker testing and the potential value of longitudinal testing in non–small cell lung cancer.